Teva Canada Innovation has evolved into a diverse company that offers innovative pharmaceuticals and healthcare solutions in the following therapeutic areas: central nervous system (CNS), pain care, respiratory, and oncology.
Teva Canada Innovation’s CNS franchise provides a complete approach to disease management, offering indispensable medicines (and patient support services) that elevate outcomes for patients living with conditions affecting the central nervous system. Our commitment to providing consistently high quality products and patient-centred care has allowed us to establish and maintain leadership in this therapeutic area.
Teva Canada Innovation's growing pain care franchise and pipeline will provide essential treatments for patients with chronic neurological disorders. We are proud to be contributing to addressing this global challenge, and to bring back a measure of quality to the lives of those patients living with pain.
Our global R&D group is developing a focused portfolio of solutions that looks across the spectrum of pain states, including chronic nociceptive pain, cancer pain, chronic neuropathic pain, and migraine.
Teva Canada Innovation's respiratory franchise provides high-quality, cost-effective treatment options uniquely designed for people with asthma. Our respiratory pipeline is centered on optimizing respiratory therapies for patients through novel delivery systems and therapies.
Teva Canada Innovation is also expanding into other respiratory therapy areas. We will continue to build upon our experience in the development, manufacture and commercialization of respiratory medicines for the treatment of asthma and COPD.
Teva Canada Innovation's oncology franchise is committed to supporting health care professionals and their cancer patients get back to the lives they want to live. With over 100 years of experience, we have developed a powerful portfolio of effective medicines to treat a range of cancers.
Teva Canada Innovation also markets brands in women’s health and has established partnerships with other Canadian pharmaceutical companies in this area.